Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor a (PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22) Leukemia (2005) The class III receptor tyrosine kinases (RTKs), which include c-FMS, c-KIT, FLT3, platelet-derived growth factor receptor a (PDGFRA) and b (PDGFRB), have been reported to be associated with the pathogenesis of an increasing number of malignancies.
1,2 PDGFRA and c-KIT are two related RTKs showing similar structure, and mutations of these genes are detected in gastrointestinal stromal tumor (GIST). 3, 4 Recently, a c-KIT D816V-activating mutation in the second tyrosine kinase (TK2) domain has been reported in patients having acute myeloid leukemia (AML) with t(8;21)(q22;q22) or inv(16)(p13q22). 5 Hence, we speculated that PDGFRA is also implicated in the pathogenesis of AML, and the mechanisms of cytogenetic progression and oncoprotein-driven function may be similar in AML expressing oncogenic forms of PDGFRA and c-KIT.
A total of 69 leukemia cell lines and 114 childhood AML samples, including those from 14 patients with t(8;21)(q22;q22) and two patients with inv(16)(p13q22) were analyzed for the expression and mutation of PDGFRA. Informed consent was obtained from the patients and/or their parents. PDGFRA gene was expressed in 28 (40.6%) of the 69 leukemic cell lines and 63 (55.3%) of the 114 AML patient samples, and direct sequencing of the samples expressing PDGFRA revealed a PDGFRA N870S mutation in a 13-yearold boy having AML-M1 with t(8;21) and a F808L mutation in a 13-year-old girl having AML-M1 with inv(16) (Figure 1a ). These missense mutations in the TK2 domain of PDGFRA are homologous to those responsible for KIT and FLT3 ligandindependent kinase activation in GIST, 3 mast cell disorders 6 and AML 7, 8 (Figure 1b) . Exon 17 mutations of Asp 816 in the TK2 domain of c-KIT are associated with mast-cell/myeloid leukemias and seminomas/dysgerminomas. 1 The transforming mechanism for these mutations is considered to involve dimer formation, resulting in constitutive ligand-independent kinase activation. 1 The PDGFRA expression was found in AML with core binding factor (CBF) translocations; 12 (85.7%) of the 14 patients with t(8;21) and two (100%) of the two patients with inv(16). The expression rate of PDGFRA in AML with CBF translocations (14 of the 16 patients, 87.5%) was significantly higher than in AML with other karyotypes (49 of the 98 patients, 50%; P ¼ 0.0059). Tumors expressing PDGFRA or KIT oncoproteins were indistinguishable with respect to activation of downstream signaling associated with tumor progression. Oncoprotein-driven signal transduction in AML is similar in GIST expressing oncogenic forms of PDGFRA and KIT. 3 Activating mutations in the c-KIT receptor gene involve point mutations in kinase domains that lead to constitutive activation of their respective receptors, and have been identified in AML. PDGFRA and c-KIT mutations may be mutually exclusive oncogenic events in AML, and these mutations may have similar biological consequences. The PDGFRA mutations in this study may be associated with ligand-independent leukemic cell growth. This is the first time that PDGFRA mutations have been detected in AML patients, and these results suggest that PDGFRA and c-KIT mutations may play similar roles in oncogenic mechanisms in AML. 
